There and Back Again an Immunotherapy Tale Pubmed

Immuno-oncology combinations: raising the tail of the survival curve

Samuel J Harris  et al. Cancer Biol Med. 2016 Jun .

Free PMC article

Abstract

There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small cell lung cancer, immune checkpoint inhibitors also appear to have significant antitumor activity in multiple other tumor types. An exciting component of immunotherapy is the durability of antitumor responses observed, with some patients achieving disease control for many years. Nevertheless, not all patients benefit, and efforts should thus now focus on improving the efficacy of immunotherapy through the use of combination approaches and predictive biomarkers of response and resistance. There are multiple potential rational combinations using an immunotherapy backbone, including existing treatments such as radiotherapy, chemotherapy or molecularly targeted agents, as well as other immunotherapeutics. The aim of such antitumor strategies will be to raise the tail on the survival curve by increasing the number of long term survivors, while managing any additive or synergistic toxicities that may arise with immunotherapy combinations. Rational trial designs based on a clear understanding of tumor biology and drug pharmacology remain paramount. This article reviews the biology underpinning immuno-oncology, discusses existing and novel immunotherapeutic combinations currently in development, the challenges of predictive biomarkers of response and resistance and the impact of immuno-oncology on early phase clinical trial design.

Keywords: CTLA4; Combination drug therapy; PD-1; PD-L1; biomarkers; clinical trials; immunotherapy; oncology.

Figures

Figure1

Current immunotherapeutic strategies with checkpoint inhibition.

Figure2

Future combination strategies with checkpoint inhibition. Multiple strategies can be used in combination with checkpoint inhibition to enhance the antitumor function of the immune system as shown. Immunogenic cell death can be promoted by chemotherapy, radiotherapy, targeted therapies as well as novel agents. Antigen presentation can be enhanced using vaccine therapies, immune adjuvants and other novel agents. Immune-suppression can be reduced or eliminated by attenuating suppressor cells and the microenvironment milieu and effector T cell function can be enhanced. TRAIL-R, TRAIL-receptor; TNF-SF, tumor necrosis factor super family; IDO1, indoleamine 2,3-dioxygenase 1; CXCR2, chemokine (C-X-C Motif) receptor 2; LAG-3, lymphocyte-activation gene 3; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; GM-CSF, granulocyte-macrophage colony-stimulating factor

Similar articles

• Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

  Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Ascierto PA, et al. J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y. J Transl Med. 2016. PMID: 27846884 Free PMC article.

• Systemic treatments for metastatic cutaneous melanoma.

  Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. Review.

• The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

  Mahoney KM, Freeman GJ, McDermott DF. Mahoney KM, et al. Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.

• [Checkpoint inhibitors for cancer therapy].

  Zander H, Müller-Egert S, Zwiewka M, Groß S, van Zandbergen G, Engelbergs J. Zander H, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Nov;63(11):1322-1330. doi: 10.1007/s00103-020-03221-9. Epub 2020 Oct 1. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 33001218 Free PMC article. Review. German.

• PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.

  Xia L, Liu Y, Wang Y. Xia L, et al. Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05. Oncologist. 2019. PMID: 30819829 Free PMC article. Review.

Cited by 36 articles

• Clinical trial data and emerging strategies: HER2-positive breast cancer.

  Pernas S, Tolaney SM. Pernas S, et al. Breast Cancer Res Treat. 2022 Jun;193(2):281-291. doi: 10.1007/s10549-022-06575-7. Epub 2022 Apr 9. Breast Cancer Res Treat. 2022. PMID: 35397080 Review.

• Immuno-oncology trends: preclinical models, biomarkers, and clinical development.

  Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Franklin MR, et al. J Immunother Cancer. 2022 Jan;10(1):e003231. doi: 10.1136/jitc-2021-003231. J Immunother Cancer. 2022. PMID: 35022192 Free PMC article. Review.

• Computational immune infiltration analysis of pediatric high-grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor location.

  Bailey CP, Wang R, Figueroa M, Zhang S, Wang L, Chandra J. Bailey CP, et al. Comput Syst Oncol. 2021 Sep;1(3):e1016. doi: 10.1002/cso2.1016. Epub 2021 Mar 8. Comput Syst Oncol. 2021. PMID: 34723252 Free PMC article.

• Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.

  Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Kelley RK, et al. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22. J Clin Oncol. 2021. PMID: 34292792 Clinical Trial.

• Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report.

  Komo T, Suzuki T, Tazawa H, Sada H, Morimoto H, Shimada N, Hadano N, Onoe T, Sudo T, Shimizu Y, Tashiro H. Komo T, et al. Int J Surg Case Rep. 2021 Jul;84:106161. doi: 10.1016/j.ijscr.2021.106161. Epub 2021 Jun 30. Int J Surg Case Rep. 2021. PMID: 34237686 Free PMC article.

References

1. 1. Coley WB. The treatment of malignat tumors by repeated inoculations of erysipelas: With areportoftenoriginalcases. The treatment of malignat tumors by repeated inoculations of erysipelas: With areportoftenoriginalcases. 1893. Clin Orthop Relat Res. 1991;262:3–11. - PubMed
2. 1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. - PMC - PubMed
3. 1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61. - PubMed
4. 1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–14. - PMC - PubMed
5. 1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27. - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

williamsbale1966.blogspot.com

Source: https://pubmed.ncbi.nlm.nih.gov/27458526/

Share this post